QRX-3 for Chronic Kidney Disease
(NAD agent Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new drug, QRX-3, to determine if it can improve kidney function in people with chronic kidney disease (CKD). CKD affects millions globally and often reduces quality of life and life expectancy. Participants will take either QRX-3 or a placebo (a pill with no active ingredients) to compare results. Suitable candidates have CKD with declining kidney function, but not too rapidly. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that QRX-3 is likely to be safe for humans?
Research has shown that QRX-3 underwent testing in earlier human trials, and these studies indicate its use without major safety concerns. This treatment aims to enhance kidney function by boosting the energy supply to cells.
QRX-3 increases a key molecule called NAD+ in the body, which may improve kidney function. Previous trials did not report serious side effects, suggesting it is generally well-tolerated. However, as with any treatment, minor side effects may occur. Discuss these with the study team before deciding to join the trial.12345Why do researchers think this study treatment might be promising?
Unlike most treatments for chronic kidney disease, which often focus on controlling symptoms like high blood pressure and diabetes, QRX-3 offers a fresh approach. Researchers are excited because QRX-3 targets the root cause of kidney damage by reducing inflammation and protecting kidney cells, potentially slowing disease progression. This oral medication, taken as two capsules twice daily, might provide a more direct and convenient treatment option compared to injections or dialysis. If successful, QRX-3 could represent a significant advancement in chronic kidney disease care, offering hope for improved kidney function and quality of life.
What evidence suggests that QRX-3 might be an effective treatment for chronic kidney disease?
Research has shown that QRX-3 could be promising for treating chronic kidney disease (CKD). This trial will evaluate QRX-3, which improves kidney function by enhancing a process important for cell energy and repair. In studies, patients using QRX-3 demonstrated better kidney function, with improvements in their glomerular filtration rate, a measure of kidney performance. QRX-3 aims to prevent kidney damage by supporting the mitochondria, the energy centers in cells. Early findings suggest it may slow CKD progression, offering hope for better disease management. Participants in this trial will receive either QRX-3 or a placebo to assess its effectiveness.14567
Are You a Good Fit for This Trial?
This trial is for individuals with chronic kidney disease (CKD) who have shown a slow decline in kidney function over the past year, specifically less than a 20% drop in eGFR. Participants must have an eGFR under 60ml/min and no signs of rapid kidney failure or acute conditions superimposed on their CKD.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive QRX-3 or placebo for the prevention and treatment of chronic kidney disease progression
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- QRX-3
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ebima Clifford Okundaye
Lead Sponsor